RecruitingNot Applicable

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

Germany200 participantsStarted 2026-02-19

Plain-language summary

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Femal patients age 18 or older at time of informed consent * Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis) * Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC) * Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025 Exclusion Criteria: * Locally advanced or metastatic breast cancer * Male patients * Patients with contraindication(s) for abemaciclib therapy according to SmPC

What they're measuring

Abemaciclib persistence rate

Timeframe: 6 months after therapy start

Trial details

NCT IDNCT07531693

SponsorInstitut fuer Frauengesundheit

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-09

Contact for this trial

Sponsor's study office

+49 15739466438 studien@ifg-erlangen.de

View on ClinicalTrials.gov More HR+/HER2- Early Breast Cancer trials